Eli Lilly and Company (LLY)
| Market Cap | 678.39B |
| Revenue (ttm) | 40.86B |
| Net Income (ttm) | 8.37B |
| Shares Out | 900.43M |
| EPS (ttm) | 9.25 |
| PE Ratio | 81.46 |
| Forward PE | 34.01 |
| Dividend | $5.20 (0.69%) |
| Ex-Dividend Date | Nov 15, 2024 |
| Volume | 5,135,903 |
| Open | 735.79 |
| Previous Close | 729.73 |
| Day's Range | 735.46 - 757.37 |
| 52-Week Range | 561.65 - 972.53 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 962.05 (+27.69%) |
| Earnings Date | Oct 30, 2024 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]
Financial Performance
In 2023, Eli Lilly's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $962.05, which is an increase of 27.69% from the latest price.
News
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle, the biotech said on Wednesday.
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
LOS ANGELES--(BUSINESS WIRE)-- #ActRII--Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer diseases, is pleased to announce a clinic...
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics' AI-Enabled, All-in-Human CONVERGE® Platform
Lilly announces changes on board of directors
INDIANAPOLIS , Nov. 19, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024. In add...
Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trial
Eli Lilly's cholesterol pill impressed in a mid-stage trial. Meanwhile, Dexcom invested $75 million in Oura.
RFK Jr.'s HHS nomination sparks concern over pharma stocks
President-elect Trump's decision to nominate Robert F. Kennedy Jr. as the Secretary of Health and Human Services (HHS) has sparked concerns, particularly about his skepticism toward the pharmaceutical...
Lilly pill cuts genetic form of cholesterol nearly 86% in study
The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on Mon...
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal of...
Medicaid dominates coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an ana...
Incyclix Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate INX-315 in Combination with Verzenio® (abemaciclib) and Fulvestrant in HR+/HER2- Breast Cancer
INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio® (abemaciclib) and fulvestrant
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an ana...
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready To Meet Demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it's unclear whether they can ramp up production enough.
Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity
In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitations Patients on tirzepatide experienced improved exercise capacity, greater weight loss and reduce...
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De...
Three-Stock Lunch: Eli Lilly, Transdigm, & Nvidia
Lee Munson, president and CIO at Portfolio Wealth Advisors, joins CNBC's ‘Power Lunch' to discuss outlooks on three stocks: Eli Lilly, Transdigm, and Nvidia.
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
Shares in some of America's largest drug manufacturers tumbled yesterday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his pick for secretary of the Department of Health and Hu...
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme...
RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr....
Lilly Sues U.S. to Change Hospital Drug Discount Payments
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain hospitals.
Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program
Eli Lilly (LLY) became the second drugmaker in recent days to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facili...
Lilly sues US agency over blocking of drug-rebate program
Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking the company's plan to change the way it offers drug discounts to hospitals.
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
On Wednesday, Eli Lilly And Co LLY released detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide.
5 Healthcare Stocks to Buy in a Beaten-Up Sector
It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.
Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
SURMOUNT-1 results show a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three years Results suggest one new case of diabetes c...
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections.